Clinical trials: Bulky Tumors
Hodgkin Lymphoma
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
The purpose of this study is to test whether BV-AVD is an effective treatment in people with early stage, bulky Hodgkin lymphoma that was recently diagnosed and who have not yet received any treatments for their disease.
- Trial name
- NCT06377566
- Testing
- Brentuximab vedotin, Doxorubicin, Vinblastine
- Where
- 8 sites in United States
- Volunteers
- 71 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cervical Cancer
Surgery With or Without Chemotherapy in Treating Patients With Stage IB Cervical Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor so that it can be removed during surgery.
- Trial name
- NCT00002536
- Testing
- cisplatin, vincristine sulfate, surgical procedure
- Where
- 41 sites in United States
- Sponsor
- Gynecologic Oncology Group
Follicular Lymphoma
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
This was a single center, single arm, phase II study. Patients with previously untreated follicular lymphoma were enrolled from the department of lymphoma, Tianjin Medical University Cancer Institute and Hospital.
- Trial name
- NCT06704555
- Testing
- radiation therapy, Tiselizumab, Rituximab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-Hodgkin's Lymphoma
A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
This study will evaluate the efficacy and safety of MabThera/Rituxan (rituximab) in treatment-naive patients with non-bulky follicular non-Hodgkin's lymphoma. The anticipated time on study treatment is 3 months.
- Trial name
- NCT01392716
- Testing
- rituximab [MabThera/Rituxan]
- Where
- 16 sites in France
- Volunteers
- 48 people
- Sponsor
- Hoffmann-La Roche
Liver Metastasis, Pelvic Cancer
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
This multi-center photodynamic therapy study plans to treat patients with large tumors in any superficial location, sarcoma, tumors of oral/oro-pharyngeal cavity, tumors with extensive pelvic involvement, or liver metastasis.
- Conditions
- Liver Metastasis, Pelvic Cancer, Head and Neck Cancer, Sarcoma
- Trial name
- NCT00028405
- Testing
- LS 11(Taporfin Sodium), Lumaflex Light Delivery Catheter
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Light Sciences LLC
Leukaemia
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
The purpose of this study was to confirm the clinical benefit observed in the pivotal registration study, Hx-CD20-406. The Committee for Medicinal Products for Human Use (CHMP) required that a randomized study be conducted in CLL…
- Trial name
- NCT01313689
- Testing
- Ofatumumab, Physicians' Choice
- Where
- 80 sites in Austria, Belgium and 15 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer
This Phase II randomized controlled study is to determine the efficacy of the preventively use of methylprednisolone after split-course chemoradiotherapy (CCRT) in locally advanced non-small cell lung cancer with bulky tumor.
- Trial name
- NCT03661567
- Testing
- chest radiation, concurrent chemotherapy, Methylprednisolone
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sun Yat-sen University
Tumor Size Greater Than or Equal to 5 cm
Efficacy and Toxicity of SCART
This study is expected to enroll patients for a period of five years, with a total of 30 participants. It is a prospective observational study involving cancer patients with tumors having a longest diameter greater than or equal…
- Trial name
- NCT06341257
- Testing
- Stereotactic Central/Core Ablative Radiation Therapy (SCART)
- Where
- Taiwan
- Sponsor
- Taichung Veterans General Hospital
Radiotherapy-Induced Immune Priming
Spatially Fractionated Radiotherapy for Tumor Treatment
To explore the efficacy and toxicity of spatially fractionated radiotherapy in the treatment of tumors.
- Trial name
- NCT07774819
- Testing
- spatially fractionated radiotherapy
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Xu Zhi-yuan
Non-small Cell Lung Cancer
Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer
This Phase II study is to determine the efficacy of Thymosin α1 on the frequency of acute pneumonia in non-small cell lung cancer with bulky tumor.
- Trial name
- NCT03659578
- Testing
- Concurrent chemotherapy, split-course radiotherapy, thymosin alpha 1
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Sun Yat-sen University
Cancer
SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors
Study Objectives Primary Objective:To evaluate the safety of SFRT followed by hypofractionated/conventional fractionated radiotherapy combined with Iparomlimab and Tuvonralimab Injection in relapsed/refractory bulky solid tumors.
- Trial name
- NCT06936748
- Testing
- Spatially Fractionated Radiation Therapy Followed by Sequential Hypofractionated or Conventional Fractionated Radiotherapy Combined with Iparomlimab and Tuvonralimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Cancer
Radiotherapy Treatment Planning Comparison Using SBRT-PATHY (Photons) Versus CARBON-PATHY for Unresectable Bulky Tumors
This study uses a novel unconventional radiotherapy technique, consisting of high dose PArtial Tumor irradiation targeting exclusively the HYpoxic segment of unresectable bulky tumors delivered either with photons (SBRT-PATHY) or…
- Trial name
- S-C-PATHY (NCT06390657)
- Testing
- Planning CT, MRI
- Where
- Austria
- Sponsor
- EBG MedAustron GmbH
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone [R-miniCHOP])…
- Conditions
- Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- Trial name
- NCT04799275
- Testing
- Biospecimen Collection, Computed Tomography, Cyclophosphamide
- Where
- 176 sites in United States
- Volunteers
- 422 people
- Sponsor
- National Cancer Institute (NCI)
PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
This was a multi-center, open-label, phase Ib/II study. The aim of the phase Ib part was to estimate the MTD(s) and/or identify the recommended phase II dose(s) (RP2Ds) for the combination of BYL719 and AMG 479 (ganitumab)…
- Trial name
- NCT01708161
- Testing
- BYL719, AMG 479
- Where
- 10 sites in United States, Belgium and 2 more
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial
This is a prospective, single-arm, multicenter phase II clinical study evaluating the efficacy and safety of spatially fractionated radiotherapy (SFRT) combined with tislelizumab and platinum-based doublet chemotherapy as…
- Trial name
- NCT07775040
- Testing
- Spatially Fractionated Radiotherapy (SFRT), Tislelizumab, Carboplatin
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Follicular Lymphoma
Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma
This Phase II trial studies the overall tumor response of vaccine therapy in patientswith previously untreated Stage III or IV, asymptomatic, non-bulky follicular lymphoma.
- Trial name
- NCT02194751
- Testing
- Oncoquest-L vaccine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- XEME Biopharma Inc.
Solid Tumor
Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
The purpose of this study is to determine whether cytoreduction of bulky metastatic disease using ultra high dose SBRT in combination with immunotherapy is tolerable and feasible In patients who have exhausted SoC treatment…
- Trial name
- NCT06416436
- Testing
- Atezolizumab, Stereotactic Ablative Radiotherapy (SBRT)
- Where
- United States
- Sponsor
- University of Kansas Medical Center
Lymphoma
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
This research is being done in order to improve treatment outcomes in patients diagnosed with bulky, early stage Hodgkin lymphoma and to reduce the side effects that are associated with use of radiation used in current…
- Trial name
- NCT01118026
- Testing
- ABVD, BEACOPP, radiation therapy
- Where
- 55 sites in United States
- Volunteers
- 101 people
- Sponsor
- Alliance for Clinical Trials in Oncology